HOME >> MEDICINE >> NEWS
Aventis Pasteur statement on HVTN 501 decision

Aventis Pasteur remains committed to the continued development of its ALVAC vector as a preventive AIDS vaccine. The knowledge gleaned from HIV Vaccine Trials Network (HVTN) 203 will be useful in moving future studies forward both in the U.S. and internationally.

There is no known correlate of protection for HIV vaccines. HVTN 501 was designed to determine possible correlates in addition to looking at efficacy of a prime-boost combination, using an ALVAC-HIV (vCP1452) prime and a gp120 boost. Because a correlate of protection analysis would not be able to be obtained from HVTN 501, that trial will not proceed. The decision, made by the NIAID and HVTN, was based on a review of data from HVTN 203 and is supported by the company.

However, the opportunity to see if the prime-boost, using ALVAC-HIV and gp120, is efficacious remains imminent. A phase III trial to be undertaken in Thailand with the Thai government and Walter Reed Army Institute of Research is planned to begin later this year. The Thai trial and HVTN 501 had different objectives. The Thai study is a straightforward community-based trial with efficacy as its outcome. The company will cooperate fully with the trial.

The NIAID and HVTN remain fully committed to several other trials using ALVAC-HIV (vCP1452) and the company intends to support them. HVTN (HIVNET) 026 looks at the safety and immunogenicity of ALVAC-HIV (vCP1452) and gp120 MN in populations outside of the U.S. HVTN 039 is studying whether a higher dose level of ALVAC-HIV (vCP1452) results in an enhanced HIV-specific immune response in vaccinees. HVTN 042 will seek to determine if there is a benefit to using a different boost, in this case lipopeptides and is in collaboration with the Agence Nationale de Recherche Sur de Sida (ANRS).

Importantly, all of these trials will help guide the companys R and D efforts in this area as well as build a continuing record of safety for these approaches. AL
'"/>

Contact: Robert Sebbag/Beth Waters
33-60-817-2183
Cooney Waters Group, Inc.
25-Feb-2002


Page: 1 2

Related medicine news :

1. Aventis Pasteur ready to meet nations needs for tetanus and diphtheria vaccine
2. Aventis Pasteur donates approximately 75 to 90 million doses of smallpox vaccine to the U.S.
3. Millennium, Aventis Pharma form novel alliance
4. Aventis Pharmaceuticals Allegra (Fexofenadine Hcl) 30-Mg tablets now available to treat seasonal allergies, chronic hives in children 6 to 11 years
5. NHLBI statement on oral contraceptive study
6. NIH panel issues State-of-the-Science statement on end-of-life care
7. Doctors statement in Mayo Clinic Proceedings reveals dark side of low-carb diets
8. American Heart Association consensus statement
9. NIA statement on IOM testosterone report
10. American Psychiatric Association issues statement on compulsive shopping
11. New statement proposes ways to stop deadly drug errors among heart, stroke patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology ... two biometric time and attendance tracking products: the new NCheck Cloud Bio Attendance ... Bio Attendance uses biometric face recognition to enable users to check in and ...
(Date:3/28/2017)... ... 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics in ... the country to sit on the 2017 National Advisory Board for Allergan’s Facial Aesthetics ... Harper helped propel the clinic from a small start-up to number 78 in the ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... Conference in Atlantic City March 13-16, was a busy spot this year. Liz ... staff discussed strategies for preventing outbreaks among camp communities during the upcoming 2017 ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... job satisfaction in their profession as their value increases in the healthcare workforce, ... provides resources such as job boards, career fairs, and candidate leads to healthcare ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... custom smile makeovers without requiring a referral. Trimble Dental offers a ... treatment, cosmetic dentistry and dental implants. Whether patients have discolored, crooked or missing ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 FinancialBuzz.com News Commentary  ... Based on New ... in states where cannabis is legal will generate $655 million in ... be from cannabis specific taxes, such as Washington State,s ... will be earned from state sales taxes that are applied on ...
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... 2017 On Friday, benchmark US ... closed the trading session up 0.19%; the Dow Jones ... was down 0.08%. US markets made broad based gains ... in green. Pre-market today, Stock-Callers.com reviews these four Medical ... WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group Inc. (NASDAQ: ...
Breaking Medicine Technology:
Cached News: